Full-Time

Lead Salesforce Software Engineer

Updated on 7/27/2026

Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

Compensation Overview

$120k - $225k/yr

+ Corporate Bonus + Incentives

Company Historically Provides H1B Sponsorship

Boston, MA, USA + 1 more

More locations: Needham, MA, USA

Hybrid

Hybrid role; 4 days on-site per week with 1 remote day.

Category
Software Engineering (1)
Required Skills
Salesforce
REST APIs

Get referred to Wellington Management

Find people who can refer or advise you

Requirements
  • 8+ years of experience in software engineering, including substantial experience designing and delivering solutions on Salesforce Sales Cloud and the Force.com platform.
  • Proven experience operating as a lead-level individual contributor, with responsibility for architectural decisions and technical direction.
  • Background in financial services or investment management, with exposure to complex business processes and regulatory considerations.
  • Strong understanding of Salesforce platform capabilities, including both declarative tools and custom development.
  • Ability to communicate clearly with both technical and non-technical audiences and influence outcomes without formal authority.
  • Deep technical expertise in Apex, Lightning Web Components, integrations (REST/SOAP), data modeling, and platform security.
Responsibilities
  • Provide architectural ownership for Salesforce Sales Cloud and Force.com–based applications supporting client and distribution functions.
  • Collaborate with other lead architects to ensure Salesforce designs align with Wellington’s broader enterprise architecture, integration patterns, and long‑term platform strategy.
  • Act as a senior technical advisor, working directly with business partners and product teams to translate requirements into clear, well‑designed technical solutions.
  • Guide solution design with a strong understanding of Salesforce platform capabilities, leveraging standard and declarative features wherever possible and applying custom development thoughtfully.
  • Establish and uphold architectural standards and best practices for Apex, Lightning Web Components, integrations, data modeling, and security.
  • Review designs and significant enhancements to ensure consistency, maintainability, and platform health over time.
  • Partner with engineers and delivery teams to ensure architectural intent is carried through implementation and ongoing evolution.
  • Work effectively with distributed and remote teams across the globe, contributing to design discussions, reviews, and decision‑making in a collaborative, inclusive manner.
  • Mentor engineers and administrators, helping raise the overall Salesforce engineering and architecture maturity.
  • Ensure Salesforce solutions meet Wellington’s enterprise controls, data protection standards, and audit expectations within a regulated financial services environment.
Desired Qualifications
  • Experience architecting Salesforce solutions supporting sales, client servicing, pipeline management, or related distribution capabilities.
  • Familiarity with enterprise integration patterns and multi‑system environments involving Salesforce.
  • Experience working with globally distributed teams across regions and time zones.
  • Salesforce certifications (e.g., Platform Developer, Application Architect, or System Architect) are a plus.
  • Experience with Agentic Development Tools
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$63.3B

Headquarters

Boston, Massachusetts

Founded

1933

Get referred to Wellington Management

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Insurance mandates support expansion in liability-aware and private-market strategies.[1]
  • Public-private market products can widen distribution across institutional client segments.[10]
  • Defined-contribution and intermediary channels offer adjacent growth beyond pensions and endowments.[7][10]

What critics are saying

  • Passive fee pressure keeps compressing active-management margins across institutional mandates.
  • Relative underperformance in flagship sleeves triggers redemptions and faster AUM decline.
  • Decentralized teams amplify key-person risk and inconsistent performance across the platform.[3]

What makes Wellington Management unique

  • Independent partnership with no chief investment officer shapes team autonomy.[3]
  • Nearly 50 teams cover equities, fixed income, multi-asset, and alternatives.[3]
  • Global private-investing franchise targets insurers, climate technology, and growth-stage companies.[1]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.